Sara Tolaney

7.2K posts

Sara Tolaney

Sara Tolaney

@stolaney1

Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls

Boston. MA Katılım Aralık 2015
625 Takip Edilen12.6K Takipçiler
Sara Tolaney retweetledi
Hope Rugo
Hope Rugo@hoperugo·
Kudos to @montypal - the new president of MOASC! Leading oncology practice in SoCal. @cityofhope @OncBrothers @OncoAlert
Sumanta K. Pal, MD, FASCO@montypal

Led my first board meeting for @MOASC_Office today! A terrific group of folks from @cityofhope, @UCIrvine, @cityofhopeoc, @KeckMedicineUSC, @CSCancerCenter & some of the largest community practice groups in our region. Terrific discussions around initiatives for fellows & junior faculty, which will be my main focus over the next 2 years! Looking fwd to seeing many of you tomorrow - will have a spectacular program w @MarlaLipsycMD, @minasedrakmd, @DoctorAKrishnan, @charlesbnguyen, @DrJZell & @PatelOncology!

English
0
5
20
2.5K
Sara Tolaney retweetledi
Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc·
📢 Join us for the 22nd Annual Young Adult Cancer Conference. This event offers a day of connection and empowerment for young adults (ages 18 to early 40s) with cancer or a blood disorder, along with their support person(s). All are welcome! 🗓️ April 11, 2026 | 9 a.m. Omni Hotel, 450 Summer St., Boston Connect with a vibrant community of peers, gain insights from engaging workshops, and share your experiences. 🎤 Hear from Boston firefighter Dan Ranahan, a dedicated member of the Boston Fire Department and the founder of the Boston Fire Cancer Foundation, who turned his personal cancer journey into a mission to support others and raise awareness. Thank you to the Timothy Roberts Reeling in a Dream Fund for making this event possible. Registration is required. Learn more and register ➡️ bit.ly/4rBKNpA
Dana-Farber’s Breast Oncology Center tweet media
English
1
3
4
747
Sara Tolaney retweetledi
NRG Oncology
NRG Oncology@NRGonc·
NRG-BR007 DEBRA: Pending Closure to Accrual: It is anticipated the targeted accrual goal of 1670 patients may be reached early April. Please continue to screen patients who have the potential to be randomized in the next several weeks.
English
0
2
6
791
Sara Tolaney retweetledi
Kazuki Nozawa, MD
Kazuki Nozawa, MD@kazuki_nozawa·
pCR after neoadjuvant chemotherapy has long been considered a strong prognostic marker. But adding ultra-sensitive ctDNA changes the picture. In the PREDICT-DNA trial (NeXT Personal @PersonalisInc ), ctDNA-negative patients among non-pCR cases showed outcomes comparable to pCR. @JCO_ASCO Small sample size—but a highly impactful finding. ascopubs.org/doi/10.1200/JC…
Kazuki Nozawa, MD tweet media
English
3
66
167
18.7K
Sara Tolaney retweetledi
Annals of Oncology
Annals of Oncology@Annals_Oncology·
🆕 April issue now online: lnkd.in/e-8MPVzU 👉 Local and locoregional prostate cancer: ESMO CPG 👉 Using AI to process unstructured health records of pts with lung cancer 👉 Imlunestrant +/- abemaciclib in ABC: updated efficacy results from the ph III EMBER-3 trial
Annals of Oncology tweet media
English
0
2
12
1.3K
Sara Tolaney retweetledi
Prof. Dr. Ahmet Dirican
Prof. Dr. Ahmet Dirican@dr_dirican·
Another new anti-HER2 therapy… SHR-A1811 (Phase 1, HORIZON-X): • mPFS: 25 months (HER2+), 11 months (HER2-low) But the real question now is: 👉 How will we choose among all these anti-HER2 options? • Which patient, which biomarker? • HER2 IHC, mutation, or liquid biopsy? • Brain metastases, visceral disease? • What is the optimal sequencing? The problem is no longer new drugs… 👉 it’s how we choose. This may well be one of the greatest challenges in the future of oncology. @oncodaily @OncBrothers @myESMO @ASCOPost @tompowles1 @Dr_Oncologista @OncoAlert nature.com/articles/s4139…
Prof. Dr. Ahmet Dirican tweet mediaProf. Dr. Ahmet Dirican tweet media
English
2
10
16
1.7K
Sara Tolaney retweetledi
Paolo Tarantino
Paolo Tarantino@PTarantinoMD·
Anti-PI3K pioneer Novartis joins the mutant-selective race by acquiring the pan-mutant-selective PI3Kα inhibitor SNV4818 novartis.com/news/media-rel…
Paolo Tarantino tweet media
English
0
13
56
3.9K
Sara Tolaney retweetledi
Elisabetta Bonzano MD, PhD
Elisabetta Bonzano MD, PhD@to_be_elizabeth·
📌 Impact of Trastuzumab Deruxtecan (T-DXd) and Brain Stereotactic Radiosurgery on Intracranial Control and Radionecrosis Risk in HER2-Positive or -Low Breast Cancer Brain Metastases 🧠 🔗 thebreastonline.com/article/S0960-… @OncoAlert #OncoAlertAF @TheBreastOnline 🔸 T-DXd combined with SRS is not associated with an increased risk of radionecrosis. 🔹T-DXd and SRS is associated with improved intracranial control outcomes. 🔸T-DXd is associated with decreased local and distant brain failure. 🔹T-DXd plus SRS could be a safe and effective strategy for HER2+ or low BCBM. Further prospective investigations are warranted to validate these results and optimize treatment sequencing.
Elisabetta Bonzano MD, PhD tweet mediaElisabetta Bonzano MD, PhD tweet media
English
1
9
19
1.7K
Sara Tolaney retweetledi
Dana-Farber’s Breast Oncology Center
Dana-Farber’s Breast Oncology Center@DFCI_BreastOnc·
We are leading a new study to evaluate the safety and effectiveness of a new drug known as #Avutometinib (#Avmapki®) in combination with the drugs #abemaciclib (Verzenio®) and #fulvestrant (Faslodex®) in metastatic hormone receptor-positive and HER2-negative (HR+/HER2-) #BreastCancer. To learn more call 877-338-7425 or visit dana-farber.org/clinical-trial… PI: @adawaksmd #MetastaticBreastCancer #MBC #ClinicalTrial #BreastCancerResearch
Dana-Farber’s Breast Oncology Center tweet media
English
1
5
11
889
Sara Tolaney retweetledi
Komal Jhaveri, MD, FACP, FASCO
Komal Jhaveri, MD, FACP, FASCO@jhaveri_komal·
DB-08 provided safety data for various strategic combinations including TDXd + ET, certainly relevant as we can use them in the residual disease setting for triple positive breast cancer @MSKCancerCenter @OncoAlert @FAndreMD #bcsm
Komal Jhaveri, MD, FACP, FASCO tweet media
Mirrors of Medicine@mirrorsmed

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer aacrjournals.org/clincancerres/… The phase Ib DESTINY-Breast08 study assessed trastuzumab deruxtecan (T-DXd) combinations in HER2-low metastatic breast cancer, establishing recommended phase II doses with capecitabine, capivasertib, anastrozole, and fulvestrant. Objective response rates ranged from 40% to 71.4% across cohorts. Grade ≥3 adverse events were common but manageable, and interstitial lung disease occurred in some patients. Overall, T-DXd combinations demonstrated encouraging preliminary efficacy with safety profiles consistent with known toxicities. #BreastCancer @jhaveri_komal @LoiSher @ErikaHamilton9 @CareyAnders1 @LauraTestaMD @FAndreMD

English
4
35
74
8.2K

Keşfet

@ESMO_Open @darioT_ @DeshmukhSachinK @DrDAbravanel @PSpanheimer @nlinmd @curijoey @DrSGraff